DESs (drug-eluting stents) oust brachytherapy for the treatment of blocked bare metal stents
This article was originally published in Clinica
Spelling the demise of vascular brachytherapy (VBT) as the standard treatment for bare metal coronary stents that have become blocked, two US studies have found that drug-eluting stents (DESs) outperform the radiation-based procedure in such cases.
You may also be interested in...
SK Biopharmaceuticals is pushing ahead with a planned sizable IPO in South Korea in June as it focuses on successfully commercializing novel anti-epileptic drug Xcopri in the US.
Lupin hopes a surge in demand for albuterol sulphate due to increased off-label use in COVID-19 patients will help its generic version, which is likely to be launched in the first half of FY21. But the Indian firm may recall a batch of metformin after the US FDA recently asked a few companies to retract extended-release versions due to NDMA concerns.
Takeda is confident about the promise of its first-in-class molecule for higher-risk myelodysplastic syndromes after positive Phase II data.